Drug Discovery World

JULY 19, 2024

Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD).

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Research Government 130

Drug Discovery World

OCTOBER 16, 2023

Professor Henrik Daub , Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases. PROTAC targeted protein degraders: the past is prologue.

Targeted Protein Degradation 147

Targeted Protein Degradation Small Molecule Molecular Biology Treatment 147

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. Conventional drug development has often focused on finding small molecules that fit the active site of a protein.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Drug Discovery World

MARCH 22, 2023

Strategic research partnerships bring together knowledge, expertise and technologies, allowing advancements in our understanding of diseases and therapeutics that would not be possible in isolation. The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington’s disease.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Drugs Licensing 130

Drug Discovery World

DECEMBER 27, 2023

Fricker was a founder of Canadian biopharma company AnorMED, acquired by Genzyme, and awarded the Queen’s Award for Technology for his participation in the development of the anticancer drug Paraplatin. He speaks about this drug discovery journey here. Listen here. Listen here. Listen here. This episode is available here.

Targeted Protein Degradation 173

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 173

Drug Discovery World

MAY 11, 2023

However, she also presented thoughts in a technical update, Targeted Protein Degradation – Progress, Direction and Prospects. In its pipeline, Imophoron is working on ADDomer based vaccines for three diseases, respiratory syncytial virus (RSV), Covid-19 and Chikungunya.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

Drug Discovery World

OCTOBER 6, 2022

This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. With key players including AstraZeneca, Bayer, Novartis and Pfizer pushing the boundaries of drug development, the reason behind this growth is evident. Volume 23 – Issue 4, Fall 2022.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130